Anti-IL-23p19 monoclonal antibody
Tildrakizumab
Brand names: Ilumetri
Adult dose
Dose: 100mg SC at week 0, 4, then every 12 weeks
Route: SC
Frequency: q12w (after loading)
Clinical pearls
- Moderate-severe plaque psoriasis
- Per NICE TA575; screen for TB/HBV before
Contraindications
- Active TB
- Active serious infection
- Hypersensitivity
Side effects
- URTI
- Injection-site reactions
- Headache
- Hepatotoxicity (rare)
Interactions
- Live vaccines
- Immunosuppressives
Monitoring
- Infections
- PASI
Reference: BNF; NICE TA575; SmPC; https://bnf.nice.org.uk/drugs/tildrakizumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Revised Original International Autoimmune Hepatitis Score (IAIHG) · Autoimmune Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Rh(D) Immune Globulin Dosage for Maternal-Fetal Haemorrhage · Haematology in Pregnancy
- AREDS Classification of Age-related Macular Degeneration · Macular Degeneration
- Diabetic Macular Oedema (DMO) Classification · Diabetic Retinopathy
- Retinopathy of Prematurity — International Classification (ICROP3) · Paediatric Retina
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD